NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor β1 production by Kim, Hye Young et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
JEM © The Rockefeller University Press $8.00
Vol. 201, No. 1, January 3, 2005 41–47 www.jem.org/cgi/doi/10.1084/jem.20041400
 
BRIEF DEFINITIVE REPORT
 
41
 
NKT cells promote antibody-induced joint 
inﬂammation by suppressing transforming 
growth factor 
 
 
 
1 production
 
Hye Young Kim,
 
1,2 
 
Hyun Jung Kim,
 
1,2 
 
Hye Sook Min,
 
1 
 
Sanghee Kim,
 
4
 
Weon Seo Park,
 
5 
 
Seong Hoe Park,
 
1,2 
 
and Doo Hyun Chung
 
1,2,3
 
1
 
Department of Pathology, 
 
2
 
Graduate School of Immunology, 
 
3
 
Rheumatism Research Center, College of Medicine, 
and 
 
4
 
Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 110-799, Korea
 
5
 
Division of Speciﬁc Organ Cancers, National Cancer Center, Gyeanggi-Do 411-069, Korea
 
Although NKT cells has been known to exert protective roles in the development of 
autoimmune diseases, the functional roles of NKT cells in the downstream events of 
antibody-induced joint inflammation remain unknown. Thus, we explored the functional 
roles of NKT cells in antibody-induced arthritis using the K/BxN serum transfer model. NKT 
cell–deficient mice were resistant to the development of arthritis, and wild-type mice 
administrated with 
 
 
 
-galactosyl ceramide, a potent NKT cell activator, aggravated arthritis. 
In CD1d
 
 
 
/
 
  
 
mice, transforming growth factor (TGF)-
 
 
 
1 was found to be elevated in joint 
tissues, and the blockade of TGF-
 
 
 
1 using neutralizing monoclonal antibodies restored 
arthritis. The administration of recombinant TGF-
 
 
 
1 into C57BL/6 mice reduced joint 
inflammation. Moreover, the adoptive transfer of NKT cells into CD1d
 
 
 
/
 
  
 
mice restored 
arthritis and reduced TGF-
 
 
 
1 production. In vitro assay demonstrated that interleukin (IL)-4 
and interferon (IFN)-
 
  
 
were involved in suppressing TGF-
 
 
 
1 production in joint cells. The 
adoptive transfer of NKT cells from IL-4
 
 
 
/
 
  
 
or IFN-
 
 
 
 
 
/
 
  
 
mice did not reverse arthritis and 
TGF-
 
 
 
1 production in CD1d
 
 
 
/
 
  
 
mice. In conclusion, NKT cells producing IL-4 and IFN-
 
  
 
play 
a role in immune complex–induced joint inflammation by regulating TGF-
 
 
 
1.
 
NKT cells express intermediate levels of a
semi-invariant V
 
 
 
14-J
 
 
 
281 (V
 
 
 
14i) TCR in
mice or an invariant V
 
 
 
24-J
 
 
 
15 TCR in hu-
mans (1), which recognizes glycolipid antigens
presented by the CD1d (2). Upon activation,
NKT cells rapidly produce large amounts of
IL-4 and IFN-
 
  
 
(3), which have been demon-
strated to play critical roles in the regulation of
innate and adaptive immune responses by
NKT cells (4). Thus, it has been proposed that
NKT cells exert regulatory functions in autoim-
mune diseases by establishing an early cytokine
environment. In animal models, NKT cells
have been reported to affect the development
and progression of diabetes mellitus (5), exper-
imental autoimmune encephalitis (6), and sys-
temic lupus erythematosus (7). However, the
functional roles of NKT cells in the develop-
ment of autoimmune arthritis have not been
completely explored.
Recently, a spontaneous murine arthritis
model was developed by breeding KRN TCR
transgenic (Tg) mice in the background of B6
to the nonobese diabetic (NOD) mice (8).
KRN TCR has been reported to be specific for
a peptide of bovine RNase (42–56) bound to
I-A
 
k 
 
presented by APCs (8). The offspring
(K/BxN) spontaneously develop a progressive
joint-specific autoimmune disease (8). In K/BxN
mice, T cells with KRN TCR recognize pep-
tide derived from glucose-6-phosphate isomerase
in the context of I-A
 
g7 
 
expressed on APCs, and
B cells produce arthrogenic Ig against glucose-6-
phosphate isomerase (9). The transfer of serum
from K/BxN mice into susceptible mice in-
duces a synchronized joint inflammation that
mimics K/BxN disease (10). Unlike other arthri-
tis animal models, the K/BxN serum transfer
model is confined to the inflammatory responses
induced by the deposition of autoantibody in
joint spaces (10). Thus, it allows one to explore
the downstream events of antibody-induced
joint inflammation and the terminal effector
mechanism of rheumatoid arthritis (RA). Re-
cently NKT cells were reported to be a sub-
population of T cells that critically exert a
functional link between innate and adoptive
immunity in immune responses in vivo (11).
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Nevertheless, the role of NKT cells at the end-stage of the ef-
fector mechanism of joint inflammation where innate im-
mune responses are critically involved remains unclear.
Our results show that NKT cells play an indispensable role
in the induction of immune complex–induced joint inflamma-
tion by suppressing TGF-
 
 
 
1 production in joint tissues, which
in turn is dependent on IL-4 and IFN-
 
  
 
secreted by NKT cells.
 
RESULTS AND DISCUSSION
NKT cells promote joint inflammation in 
the antibody-induced arthritis
 
To determine the specific role of NKT cells in the develop-
ment of antibody-induced arthritis, we examined NKT cell–
deficient mice, CD1d
 
 
 
/
 
  
 
and J
 
 
 
281
 
 
 
/
 
  
 
mice, and B6 mice
in the K/BxN serum transfer model. Whereas B6 mice
showed measurable swelling at 3–4 d after serum transfer,
which peaked at 8–9 d, CD1d
 
 
 
/
 
  
 
and J
 
 
 
281
 
 
 
/
 
  
 
mice were
resistant to the development of joint inflammation for 6 d
and showed a gradual increase in ankle swelling after 7 d
(Fig. 1 A). The maximal thickness of joint swelling in
CD1d
 
 
 
/
 
  
 
and J
 
 
 
281
 
 
 
/
 
  
 
mice was much smaller than that of
B6 mice. Histological examination of the ankle joints of B6
mice at 5 d revealed a marked infiltration of neutrophils in
synovial fluid and connective tissues (Fig. 1 B). Unlike B6
mice, CD1d
 
 
 
/
 
  
 
and J
 
 
 
281
 
 
 
/
 
  
 
mice showed mild inflamma-
tory cell infiltration in ankle joints and surrounding connec-
Figure 1. NKT cell–deficient mice attenuate arthritis in the K/BxN 
serum transfer model. (A) Clinical scores and ankle thickness was moni-
tored in J 281 /  (black triangle), CD1d /  (black circle), and B6 mice 
(black square) after injection of K/BxN serum. (B) Histological examination 
of the ankle joint of a B6 mouse and of J 281 /  and CD1d /  mice 5 d 
after serum transfer. A magnification of 12.5 in the top panels and 40 in 
the bottom panels. (C) RT-PCR was used to determine the level of 
V 14J 281 TCR mRNA in the ankle joint tissues of B6 mice and CD1d /  
mice 3, 5, 7, and 14 d after K/BxN serum transfer. (D) Sorted NKT cells (3   105 
cells/mouse) from B6 mice (white square) were adoptively transferred into 
CD1d /  mice 1 d before K/BxN serum transfer. Clinical scores and ankle 
thickness were monitored and compared with B6 (black square) and 
CD1d /  mice (black circle). Data are the means   SEM of three mice in 
each group. These results are taken from a representative one of six re-
peated experiments (A and C). 
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tive tissues (Fig. 1 B). To test for the infiltration of NKT
cells in joint tissues, we measured the level of V
 
 
 
14J
 
 
 
281
TCR mRNA in the joint tissue of B6 mice after K/BxN se-
rum transfer. RT-PCR assays showed V
 
 
 
14J
 
 
 
281 TCR
mRNA at 3, 5, and 7 d after serum injection and weak in-
tensity band on day 14, which was not demonstrated in
CD1d
 
 
 
/
 
  
 
mice (Fig. 1 C). However, no transcripts for
V
 
 
 
14J
 
 
 
281 TCR were detected in the joint of B6 mice at
day 0, indicating that NKT cells infiltrate joint tissues during
antibody-induced arthritis (not depicted). To demonstrate
that the lack of NKT cells specifically caused the failure of
CD1d
 
 
 
/
 
  
 
mice to develop arthritis, we adoptively trans-
ferred NKT cells from normal B6 mice (Fig. 1 D) into
CD1d
 
 
 
/
 
  
 
mice. Joint swellings in CD1d
 
 
 
/
 
  
 
mice transferred
with the NKT cells of normal B6 mice were as thick as those
of B6 mice. Furthermore, joint swellings in CD1d
 
 
 
/
 
  
 
mice
transferred with splenocytes from RAG
 
 
 
/
 
  
 
V
 
 
 
14
 
tg
 
 V
 
 
 
8.2
 
tg
 
(V
 
 
 
14J
 
 
 
281 TCR Tg RAG
 
 
 
/
 
 
 
) mice were as thick as those
of B6 mice, whereas CD1d
 
 
 
/
 
  
 
mice transferred with spleno-
cytes from J
 
 
 
281
 
 
 
/
 
  
 
mice did not develop joint inflamma-
tion (Fig S1 A, available at http://www.jem.org/cgi/content/
full/jem.20041400/DC1). Splenocytes from V
 
 
 
14J
 
 
 
281 TCR
Tg RAG
 
 
 
/
 
  
 
mice contain a large number of V
 
 
 
14i TCR
NKT cells in the absence of conventional 
 
   
 
T cells and B
cells compared with those from C57BL/6 mice, whereas the
splenocytes of J
 
 
 
281
 
 
 
/
 
  
 
mice are deficient in V
 
 
 
14i TCR
NKT cells (4). These data indicate that adoptively transferred
NKT cells restored arthritis in CD1d /  mice in the K/BxN
serum transfer model. Next, we investigated whether the
activation of NKT cells affects arthritis using  -galactosyl
ceramide ( -GalCer), a potent NKT cell stimulant. When
we injected B6 mice with  -GalCer, joint swelling in these
mice was aggravated (Fig. 2). These data indicate that the
in vivo activation of NKT cells using  -GalCer aggra-
vated joint inflammation during K/BxN serum–transferred
arthritis.
It has been reported that patients with RA have abnor-
malities in the number of TCR  V24   V11  double nega-
tive NKT cells in peripheral blood lymphocytes compared
with healthy persons (12). In the mouse system, the adminis-
tration of OCH, a sphingosine-truncated analogue of  -Gal-
Cer, into B6 mice inhibits collagen-induced arthritis (13).
These results provide supporting evidence of the protective
roles of NKT cells in autoimmune arthritis. However, our
results demonstrate that NKT cells provoke inflammatory re-
sponses in the joint tissues of the K/BxN serum transfer
model. Theses contradictory findings for the functional roles
of NKT cells in joint inflammation led us to speculate that
NKT cells play diverse roles in autoimmune arthritis depend-
ing on the disease processes. In the K/BxN serum transfer
model, the immune complexes on the cartilage surface were
found to engage Fc RIII on mast cells and macrophages in
the synovium (8, 14). These findings indicate that the
K/BxN serum transfer model is one of the typical Arthus re-
actions, which does not include adoptive immune responses.
Thus, the provocative roles of NKT cells in the K/BxN se-
rum transfer model represent a novel function in immune
complex–induced inflammatory responses and not the sup-
pressive role of NKT cells described in adoptive autoimmune
responses (5, 15). However, NKT cells play different roles in
different models for antibody-induced autoimmune diseases.
A recent report has provided evidence that  -GalCer sup-
presses disease in a model for Graves’ thyroiditis (16), whereas
the functional roles of NKT cells was not found in an experi-
mental autoimmune myasthenia gravis model (17). Taken to-
gether, it is conceivable that NKT cells have a dual func-
tionality that depends on the disease processes of RA, a
suppressive role in the inductive phase, and a provocative role
with respect to antibody-induced joint inflammation.
TGF- 1 exerts antiinflammatory effects on 
antibody-induced arthritis
To evaluate the mechanism by which NKT cells contribute
to the development of arthritis, we measured the mRNA
levels of various proinflammatory cytokines in joint tissues.
Upon K/BxN serum transfer, CD1d /  mice showed higher
levels of the TGF- 1 transcript, whereas B6 mice showed
reduced levels of the TGF- 1 transcript on days 3, 5, 7, and
14. Conversely, IFN-  and IL-4 were lower in CD1d / 
mice than in B6 mice (Fig. 3 A). In contrast to joint tis-
sues, the transcript levels of TGF- 1, IL 4, and IFN- 
in the spleen were similar in B6 and CD1d /  mice in
the K/BxN serum transfer model (Fig. 3 B). The reconstitu-
tion of CD1d /  mice with either NKT cells from B6 or
V 14J 281 TCR Tg RAG /   mice reduced TGF- 1
mRNA and increased the levels of IFN-  and IL-4 transcript
in the joint tissues (Fig. 3 B and Fig. S1 B). In contrast, the
adoptive transfer of NKT cells did not alter the transcript
level of TGF- 1 or IFN-   and IL-4 in the spleens of
CD1d /  mice (Fig. 3 B). These results suggest that the
TGF- 1 might be involved in the resistance to joint inflam-
mation shown by CD1d /  mice, and this is tightly regu-
lated by NKT cells infiltrating joint tissue in the K/BxN se-
rum transfer model. To establish a functional link between
TGF- 1 activity and arthritis, a blocking anti–TGF-  mAb
and recombinant TGF- 1 were injected i.p into CD1d / 
and B6 mice in a K/BxN serum transfer model. TGF- 1
Figure 2. The administration of  -GalCer into B6 mice aggravates 
arthritis. B6 mice were injected with 1  g  –GalCer (white square) three 
times a week before and after the administration of 70  l K/BxN serum 
and are compared with B6 (black square), CD1d /  (black circle), and 
 –GalCer–injected CD1d /  mice (white circle). Data are the means   
SEM of four mice in each group. The statistical analysis was performed 
using the Prism 3.0 program. *, P   0.05; **, P   0.01; ***, P   0.001.NKT CELLS PROMOTE ANTIBODY-INDUCED ARTHRITIS | Kim et al. 44
blockade in CD1d /  mice induced a significant increase in
joint swelling and clinical index, whereas TGF- 1 blockade
in B6 mice did not apparently increase joint inflammation
(Fig. 3 C). The recombinant TGF- 1 administered into B6
mice suppressed joint inflammation as compared with B6
mice in the serum transfer model (Fig. 3 D). These findings
revealed that the regulatory effects of NKT cells on arthritis
depend on the amount of TGF- 1 produced in joint tissues.
However, the roles of NKT cells as effector cells were not
completely ruled out in antibody-induced joint inflamma-
tion. Therefore, its effector functions in this model should
be explored further.
In animal models, TGF- 1 down-regulates proinflam-
matory cytokine production and exerts protective effects on
collagen-induced arthritis in mice (18). Conversely, it has
been demonstrated that TGF-  is also capable of promoting
inflammation by enhancing neutrophilic infiltration and the
induction of angiogenesis in joint tissues (19). Thus, it has
been suggested that the balance between the proinflamma-
tory and antiinflammatory effects of TGF-  in joint inflam-
mation is crucial to RA outcome (20).
TGF- 1 production in synovium is suppressed by IL-4 
and IFN-  secreted by NKT cells
To explore how NKT cells induce arthritis by regulating the
production of TGF- 1 in our model, synovial cells were
taken from mice treated with K/BxN serum and then cul-
tured with Con A to induce the production of TGF- 1.
TGF- 1 production was suppressed by the activation of
NKT cells using  -GalCer and restored by blocking the in-
teraction between CD1d and TCR on NKT cells with anti-
CD1d mAb (Fig. 4 A). Furthermore, when we injected B6
Figure 3. TGF- 1 exerts antiinflammatory effects on the joint tissues 
of CD1d /  mice in the K/BxN serum transfer models. (A) The tran-
script levels of IL-4, IFN- , and TGF- 1 were measured by real-time PCR in 
joint. (B) The sorted NKT cells of B6 mice were reconstituted in CD1d /  
mice. The transcript levels of TGF- 1, IL 4, and IFN-  were measured by 
real- time PCR in the joint tissues and the spleens. (C) 500  g anti–TGF- 1 
mAb was injected i.p. into CD1d /  mice three times per week before and 
after the administration of K/BxN serum. Ankle thickness was monitored 
in B6 (black square), CD1d /  (black circle), control IgG–injected CD1d /  
(gray circle), and B6 (gray square) mice, and anti–TGF- 1 mAb–injected 
CD1d /  (white circle) and B6 mice (white square). (D) B6 mice were in-
jected i.p. with recombinant TGF- 1 during the development of arthritis. 
Joint swelling was measured and compared with B6 (black square), CD1d /  
(black circle), and recombinant TGF- 1–injected B6 mice (white square). 
Data are the mean   SEM of three mice in each group.JEM VOL. 201, January 3, 2005 45
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mice with  -GalCer, TGF- 1 production in joint tissues was
reduced versus control mice in the K/BxN serum transfer
model (Fig. 4 B). These results indicate that activated NKT
cells specifically suppress the production of TGF- 1 by im-
mune cells of synovium. It is well known that NKT cells se-
cret IL-4, IFN-  , and IL-13 and enhance the production of
IL-10 in vivo upon activation (3, 4, 21). Thus, we attempted
to identify cytokines involved in the suppression of TGF- 1
production by NKT cells. IL-4, IL-10, IL-13, and IFN- 
were neutralized by specific mAbs during synovial and NKT
cell activation in culture. Among the blocking mAbs tested,
mAbs against IL-4 and IFN-  partially restored TGF- 1 pro-
duction, whereas mAbs against IL-10, IL-13, and control IgG
had no effect (Fig. 4 A). These results suggest that IL-4 and
IFN-  secreted by NKT cells might be involved in the sup-
pression of TGF- 1 production by synovial cells. Interest-
ingly, a recent report provided evidence that CD1d-restricted
T cells promote TGF-  production through IL-13 using a tu-
mor model (22). However, IL-13 did not seem to be a major
regulatory cytokine for production of TGF- 1 in the K/BxN
serum transfer model (Fig. 4 A). Next, we determined
whether these cytokines secreted by NKT cells play critical
roles in the development of joint inflammation and in the
suppression of TGF- 1 production in vivo. We transferred
sorted NKT cells from either IL-4 /  or IFN-  /  mice into
CD1d /  mice in the K/BxN transfer model and measured
joint swelling and the transcriptional level of TGF- 1 in joint
tissues. Joint swelling in CD1d /  mice adoptively transferred
with NKT cells from IL-4 /  or IFN-  /  mice was minimal
as in CD1d /   mice, whereas CD1d /   mice adoptively
transferred with NKT cells from normal B6 showed joint
swelling as in B6 (Fig. 4, C and D). TGF- 1 was increased at
the transcript level in CD1d /  mice adoptively transferred
with NKT cells from IL-4 /   or IFN-  /   mice versus
CD1d /  mice transferred with NKT cells from B6 (Fig. 4, C
and D). Furthermore, the blockade of either IL-4 or IFN- 
using neutralizing mAb in V 14J 281 TCR Tg RAG / 
mice resulted in resistance to the development of joint inflam-
mation and enhanced TGF- 1 production in joint tissues
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20041400/DC1). Thus, these results suggest that NKT
cells induce arthritis by suppressing TGF- 1 by producing IL-4
and IFN-  in vivo. Several experiments demonstrated that
IFN-  is a negative regulator of TGF-  production and of
the effects of TGF-  on immune cells in vivo and in vitro
(23, 24). These findings explain how IFN-  regulates joint
inflammation by suppressing TGF- 1 production in joint tis-
sue. On the contrary to previous studies reporting that IL-4
promotes the differentiation of TGF- –producing CD4  T
cells (23), our study shows that IL-4 secreted by NKT cells
suppress the production of TGF- 1 in joint tissues. It remains
unclear how IL-4 suppresses TGF- 1 production in the joint
tissues of the K/BxN serum transfer model. Thus, we specu-
late that the effects of IL-4–induced cytokine production
might be diverse depending on the different maturational
stage of the responding cells and/or the murine model system.
Nevertheless, the mechanism for the suppression of TGF- 1
by IL-4 in this model should be explored further.
In summary, our studies suggest that NKT cells in joint
tissue may play an essential role in the end-stage effector
phase of RA, and that inflammatory responses in RA might
be regulated by modulating NKT cells in joint tissues.
MATERIALS AND METHODS
Mice. KRN TCR Tg mice and NOD mice were provided by D. Mathis
and C. Benoist (Harvard Medical School, Boston, MA) and from the Institut
Figure 4. The suppressive effects of NKT cells on TGF- 1 produc-
tion in joint tissues are dependent on IL-4 and IFN-  secreted from 
NKT cells. (A) Synovial cells were taken from B6 mice treated with K/BxN 
serum and cultured with Con A and  -GalCer. IL-4, IL-10, IL-13, and IFN-  
were neutralized, and CD1d was blocked using mAbs during synovial cell 
activation. TGF- 1 production by synovial cells was determined by ELISA. 
(B) B6 mice were injected with  –GalCer, and TGF- 1 transcrit levels were 
measured in the ankle joint tissues by real-time PCR. (C) Sorted NKT cells 
(5   106 cells/mice) from IL-4 /  (white circle), (D) IFN-  /  mice (white 
circle), and B6 (white square) were adoptively transferred into CD1d /  
mice in the K/BxN serum transfer model. Joint swelling was measured and 
compared with B6 (black square) and CD1d /  controls (black circle). The 
level of TGF- 1 mRNA was measured in the ankle joint tissues of B6, 
CD1d / , and CD1d /  mice treated with either sorted NKT cells from B6 
or IL-4 /  or IFN-  /  mice by real-time PCR 7 d after serum transfer.NKT CELLS PROMOTE ANTIBODY-INDUCED ARTHRITIS | Kim et al. 46
de Génétique et de Biologie Moléculaire et Cellulare, and were maintained in
a C57BL/6(B6) background (K/B). Arthritic mice (K/BxN) were obtained
by crossing K/B with NOD (N) mice. CD1d /  mice were provided by Hua
Gu (Columbia University, New York, NY). J 281 /  and RAG    V 14tg
V 8.2tg (V 14J 281 TCR Tg RAG   ) mice were provided by M. Tanigu-
chi (Chiba University, Chiba, Japan). IL-4 /  and IFN-  /  mice were pur-
chased from The Jackson Laboratory. B6 mice were purchased from DaeHan
Biolink. These mice were bred and maintained under specific pathogen-free
conditions at the Clinical Research Institute Seoul National University Hos-
pital (CRISNUH). All animal experiments was performed after receiving ap-
proval of the Institutional Animal Care and Use Committee of CRISNUH.
Serum transfer and arthritis scoring. Arthritic adult K/BxN mice
were bled and sera were pooled. Recipient mice were injected i.p. with 150
 l (except for the experiment for  -GalCer stimulation in vivo) of pooled
K/BxN sera on days 0 and 2. Ankle thickness was measured with a caliper
(Manostat). Joint swellings were monitored and scored as follows. 0, no
joint swelling; 1, swelling of one finger joint; 2, mild swelling of wrist or
ankle; 3, severe swelling of wrist or ankle.
Histological examination. Whole knee joints and hind paws were fixed
in 10% formalin, decalcified, and paraffin embedded. Sections were pre-
pared from the joint tissue blocks and stained with hematoxylin and eosin.
Adoptive transfer experiment. After mice were killed, livers were ho-
mogenized and resuspended in loading buffer (PBS plus 10% FBS and 1
mM EDTA) and overlaid onto lympholyte-M (Cedarlane). After centrifu-
gation for 20 min at 900 g at 25 C, liver mononuclear cells were isolated
from the interface. Obtained cells were stained with PE-conjugated anti-
NK1.1 (BD Biosciences) and CyChrome-conjugated anti-TCR  (BD Bio-
sciences). Stained cells were then sorted by FACStarPlus using CELLQuest
software, and the purity of sorted cells was  98%.
Real-time PCR and RT-PCR analysis. The joint tissues were homog-
enized using a Polytron and TRIzol reagent, and total RNA was isolated. 5
 g RNA was reverse transcribed with Molony Munne Leukemia virus RT
(Koschem) and then PCR was performed. The following primers were syn-
thesized by Applied Biosystems: GAPDH: TGCACCACCAACTGCTTA
forward, GGATGCAGGGATGATGTT reverse, and CAGAAGACT-
GTGGATGGCCCCTC-VIC; IFN- : AGCAACAGCAAGGCGAAAA
forward, CTGGACCTGTGGGTTGTTGA reverse, and CTCAAACT-
TGGCAATACTCATGAATGCATC-TAMRA; TGF- 1: GCAACAT-
GTGGAACTCTACCAGAA forward, GACGTCAAAAGACAGCCAC-
TCA reverse, and ACCTTGGTAACCGGCTGCTGACCC-TAMRA.
The real-time PCR primer for IL-4 was purchased from Biosource Interna-
tional. The results for each cytokine are normalized with respect to
GAPDH expression. The primers for V 14J 281 TCR are CTAAGCA-
CAGCACGCTGCACA forward and AGGTATGACAATCAGCTGA-
GTCCC reverse.
Synthesis of  -GalCer.  -GalCer was synthesized using the method de-
veloped by Kim et al. (25).
Cytokine neutralization and ELISA. Synovial cells were taken from
B6 mice, administrated K/BxN serum, and cultured with Con A (Sigma-
Aldrich) and  -GalCer. Anti–IL-4, anti–IL-10, and anti–IL-13 mAbs
(R&D Systems) and anti–IFN-  mAb (American Type Culture Collection
[ATCC]) were used to neutralize the respective cytokines in the concentra-
tion of 50  g/ml. CD1d was blocked using 5  g of blocking mAbs (BD
Biosciences) during synovial cell activation. TGF- 1 production was mea-
sured using ELISA (BD Biosciences). The hybridomas for anti–TGF- 
(clone:1D11.16.8), anti–IFN-   (clone: R4-6A2), and IL-4 mAb (clone
HB188) were purchased from ATCC. 500  g of each mAb was injected
i.p. three times per week. 1  g rhTGF- 1 (R&D Systems) was injected i.p.
into B6 mice twice before and after the administration of K/BxN serum.
Online Supplemental Materials. Fig. S1 shows that the adoptive trans-
fer of V 14i cells restores joint inflammation and suppresses TGF- 1 pro-
duction in CD1d /  mice. Fig. S2 shows that the blockade of IL-4 or IFN- 
in V 14J 281 TCR Tg RAG /  mice reduces joint inflammation and does
not suppress TGF- 1 production in synovium. Figs. S1 and S2 are available
at http://www.jem.org/cgi/content/full/jem.20041400/DC1.
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